• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika extends deal with UMass Amherst to develop rheumatoid arthritis therapy

January 25, 2018 By Sarah Faulkner

Anika TherapeuticsAnika Therapeutics (NSDQ:ANIK) has inked a deal to extend its two-year-long collaboration with the Institute for Applied Life Sciences at the University of Massachusetts Amherst.

The group plans to focus its efforts on developing a novel therapeutic candidate to treat rheumatoid arthritis. Anika and UMass reported that it hopes to bring the product into clinical trials to support a potential regulatory submission.

“We’re excited to renew our partnership with UMass Amherst and its world-renowned research faculty to continue developing a targeted, localized therapy that could address an unmet medical need in rheumatoid arthritis,” Anika CEO Charles Sherwood said in prepared remarks.

“Our collective efforts to date have produced a promising therapeutic candidate, encompassing a novel drug delivery system for which patent protection is being sought. We’re confident that the next phase of this collaboration, which will focus on formulating our lead candidate and preparing for clinical development, will prove equally fruitful and advance Anika’s mission to deliver novel therapies that address the full continuum of orthopedic care.”

“The initial success of our collaboration with Anika is solid evidence that industry allying with academia can drive game-changing innovation and accelerate the pace of development,” Mike Malone, UMass Amherst’s vice chancellor for research & engagement, added.

“We are looking forward to further advancing innovative discoveries from UMass laboratories with expertise in inflammation and novel drug delivery technology and therapeutic cargo combinations, to bring much-needed treatment options to people living with rheumatoid arthritis,” Peter Reinhart, director of the Institute for Applied Life Sciences, said.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Anika Therapeutics Inc.

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS